Canadian cannabis company Aurora Cannabis Inc. has announced that its wholly owned subsidiary Pedanios GmbH is collaborating with Heinrich Klenk GmbH & Co. KG, which is one of the largest medicinal plant companies in Europe. Heinrich Klenk is based in Schwebheim, Germany.
Under the terms of the collaboration agreement entered into by Pedanios and Heinrich Klenk, Aurora Cannabis launched a new brand of cannabis product in Germany called Cannabis Klenk. This new brand will be produced in Canada and will be imported by Pedanios, then Heinrich Klenk will sell it to German pharmacies through its existing pharmaceutical wholesale distribution network.
Heinrich Klenk has been exporting, processing, and importing medicinal plants and herbal raw materials for over nine decades for the pharmaceutical industry all throughout Germany and other European countries. Heinrich Klenk’s wide-reaching distribution network consists of over 25,000 pharmacies throughout Europe.
Heinrich Klenk’s medicinal plant products boast premium quality and they are made available all across Germany and Europe through almost a century of relationships with the continent’s top pharmaceutical wholesale distributors.
According to Neil Belot, Aurora Cannabis Chief Global Business Development Officer, Heinrich Klenk is a great partner for the Canadian cannabis giant because it will enable them to add to their presence in the German market. They believe that Heinrich Klenk’s comprehensive distribution network will help destigmatize medical cannabis use in Germany even further and will help accelerate the growth of the legal cannabis industry in the country.
What’s more, Belot adds that Heinrich Klenk’s decentralized distribution capabilities will ensure short supply lines, as well as increase their market reach while also reducing the need to heavily invest in its own sales capabilities.
Currently, products under the Cannabis Klenk brand are held in more than 20 distribution hubs across Germany. This will help facilitate fast and convenient access, as well as allow same-day delivery service to partner-pharmacies.
Aurora launches Aurora Frost
Aurora Cannabis has also launched a new line of dried cannabis products named Aurora Frost. This new line offers over 35% tetrahydrocannabinol (THC) potency, representing the highest THC content offered by Aurora in any of its products so far.
Aurora Frost products are made from premium whole flower. These products are generally known as kief, and they primarily consist of trichomes. Trichomes are the resinous glands that are abundant in active pharmaceutical ingredients like terpenes, cannabinoids like CBD and THC, and flavonoids.
The company’s technology team was able to successfully develop a new and proprietary technology that was used to produce high volume, GMP-compliant, Aurora Frost products efficiently. This technology is based on a process that trims the trichomes finely from cannabis flower.
Aurora Frost is shipped in child-safe, certified glass bottles. The products are available in one-gram increments and are priced at $35 per gram (or $25 per gram for compassionate pricing patients).
And just like all other products from Aurora, Aurora Frost comes with third-party independent laboratory results that are publicly available. These lab results pertain to the product’s potency, contaminant analysis, and terpene profile.
About Aurora Cannabis
Aurora Enterprises Inc., which is Aurora’s wholly-owned subsidiary, is a licensed medical cannabis producer pursuant to Health Canada’s ACMPR or Access to Cannabis for Medical Purposes Regulations. Aurora operates a 55,200-sq.ft., cutting-edge and state-of-the-art production facility located in Mountain View County, Alberta, as well as a second 40,000-sq.ft. high-technology production facility in Pointe-Claire, Quebec. In January 2018, Aurora Sky, which is Aurora’s 800,000-sq.ft. flagship cultivation facility at the Edmonton International Airport, was licensed. Aurora Sky is projected to produce over 100,000 kg of cannabis annually. The company is also completing a facility in Lachute, Quebec, through another wholly owned subsidiary, Aurora Larssen Projects Inc.
Aurora’s new wholly owned subsidiary, CanniMed Therapeutics Inc., is Canada’s most experienced licensed medical cannabis producer, boasting over 20,000 kg annually in funded capacity. It is CanniMed that forms the heart of the company’s Medical Cannabis Centre of Excellence, which is aimed at market and product development.